Clinical Trial Update: A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 [Phase 3]

View source ↗

Summary

Phase IIIa study of a genetically modified recombinant human interleukin-11 for chemotherapy-induced thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia

Drugs mentioned

• Genetically Modified Recombinant Human Interleukin-11 (interleukin-11)

Snippet

Sponsor: Beijing Northland Biotech. Co., Ltd. | Conditions: Chemotherapy-induced Thrombocytopenia | Phase 3 | Status: COMPLETED